Demetra Holding, an innovative and independent international medical company leader in providing anti-infective cements, spacers, and biomaterials for orthopedic applications, acquired a 51% stake in GetSet Surgical, a leading Swiss-based spine surgical solutions provider.

The acquisition marks a significant step in Demetra Holding’s strategy to broaden its offerings in the Spine sector. Demetra’s existing technologies will combine with GetSet’s expertise in sterile spine procedure kits, creating a comprehensive spinal/orthopedic product lineup designed to reduce infection risks, optimize hospital efficiency, and contribute to environmental sustainability.

As part of its expansion plans, Demetra Holding is prioritizing the introduction of GetSet’s products into the United States market. The newly established US Spine Division of Demetra’s portfolio company OsteoRemedies will manage the distribution of these products. This division will be headed by Ted Bird, an industry veteran recently appointed Vice President of Spine Commercial.

Michele Perrino, CEO of Demetra Holding, commented: “Demetra Holding is proud to spearhead this collaboration, as it aligns perfectly with our mission to enhance healthcare solutions focused on orthopedic infection management strategies worldwide. By combining the innovative capabilities of GetSet Surgical with our existing product offerings, we are striving to create and become the premier choice for surgeons and their patients in the single-use, sterile packaged spinal procedure market.”

Ole Stoklund, founder and CEO of GetSet Surgical stated: “The integration of GetSet’s cutting-edge sterile packaged spine procedure kits with Demetra Holding’s robust portfolio and resources will significantly enhance our mutual commitment to minimizing infection risks and optimizing operational efficiencies in hospitals and the emerging ASC market.”

The use of sterile-packaged disposable implants and instruments helps to reduce the risk of infections and hospital costs associated with central sterilization issues, aligning directly with Demetra’s mission of becoming the company of choice for infection management and efficiency through its portfolio companies: Tecres, OSARTIS, OsteoRemedies and Yijiutai.